Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13212857 | 0.90 | HRH3 (0.38) | ACHECHRM3CHRM1CHRM2CHRM4 | |
| SCHEMBL19652091 | 0.86 | DPP4 (0.39) | EGLN1CHRM3JAK1JAK2HRH3 | |
| SCHEMBL13860739 | 0.79 | HRH3 (0.36) | HRH3KCNH2 | |
| SCHEMBL19658759 | 0.77 | ACHE (0.53) | ACHECHRM3CHRM1CHRM2CHRM4 | |
| SCHEMBL24179679 | 0.77 | EGLN1 (0.31) | EGLN1JAK1JAK2HRH3 | |
| SCHEMBL16565487 | 0.77 | JAK1 (0.48) | EGLN1JAK1JAK2HRH3KCNH2 | |
| SCHEMBL17190311 | 0.76 | HRH3 (0.36) | CHRM3HRH3KCNH2ALDH1A1 | |
| SCHEMBL1781781 | 0.75 | EGLN1 (0.33) | EGLN1HRH3 | |
| SCHEMBL19658448 | 0.75 | ACHE (0.42) | EGLN1ACHECHRM3CHRM1CHRM2 | |
| SCHEMBL1781783 | 0.75 | HRH3 (0.31) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | EGLN1 3302/4885ACHE 2649/4885CHRM3 1613/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | EGLN1 3302/4885ACHE 2649/4885CHRM3 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.